Analysts Caution Against Overreacting To Biogen's Alzheimer's Trial Change
February 15, 2018 at 14:25 PM EST
Biogen said the company has decided to add 510 patients to the Phase 3 aducanumab trials after seeing more "variability" than expected in a sample size re-estimation, sending its shares into negative territory.